Syntarga B.V. is a biopharmaceutical company creating innovative chemistries to link anticancer activity to specificity. The Company develops highly potent cell-killing drugs, releasable linker technologies and linker-drug combinations for conjugation to tumor-specific antibodies and mAb derivatives. Syntarga focuses its activities on the development of complete antibody payload chemistries, which, in combination with a third party antibody, yield successful Antibody-Drug Conjugate (ADC) products.